Targeting CMTM6 Suppresses Stem Cell–Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Lei Chen¹, Qi-Chao Yang¹, Yi-Cun Li¹, Lei-Lei Yang¹, Jian-Feng Liu¹, Hao Li¹, Yao Xiao¹, Lin-Lin Bu¹, Wen-Feng Zhang¹,², and Zhi-Jun Sun¹,²

ABSTRACT

CMTM6, a regulator of PD-L1 expression, also modulates tumor immunity. Little is known about the function of CMTM6 and its mechanism of action in head and neck squamous cell carcinoma (HNSCC). In this study, we found by IHC analysis that CMTM6 overexpression predicted a poor prognosis for patients with HNSCC. We discovered that CMTM6 expression was correlated with increased activity through the Wnt/b-catenin signaling pathway, which is essential for tumorigenesis, maintenance of cancer stem cells (CSC), and the epithelial-to-mesenchymal transition (EMT) characteristic of multiple cancers. We used short hairpin RNA to eliminate expression of CMTM6, which led, in HNSCC cells, to reduced expression of nuclear b-catenin as well as inhibition of stem cell–like properties, TGFb-induced EMT, and cell proliferation. Consistent with these results, we identified a significant positive correlation between expression of CMTM6 and EMT- and CSC-related genes in The Cancer Genome Atlas (TCGA). We found positive correlations for both RNA and protein between expression of CMTM6 and immune checkpoint components. CMTM6 silencing–induced PD-L1 downregulation delayed SCC7 tumor growth and increased CD8⁺ and CD4⁺ T-cell infiltration. The proportions of PD-1⁺, TIM-3⁺, VISTA⁺, LAG-3⁺, and B7-H3⁺ exhausted T cells were decreased significantly in the CMTM6 knockdown group. CMTM6 thus regulates stemness, EMT, and T-cell dysfunction and may be a promising therapeutic target in the treatment of HNSCC.

Introduction

Head and neck squamous cell carcinoma (HNSCC), a heterogeneous epithelial tumor, is the sixth most common malignancy among approximately 600,000 patients per year worldwide, with a mortality of 40%–50% (1, 2). Alcohol, betel quid, and tobacco exposure are the major causes of HNSCC (3, 4). Human papillomavirus (HPV) infection is an independent risk factor for oropharyngeal tumors, which occur primarily in the Western world (4, 5). The 5-year survival rate of HNSCC has not improved over the past three decades, despite improvements in therapeutics (6). The low survival rate is mainly due to recurrence and metastases (3). A better understanding of the molecular mechanisms of tumorigenesis is needed for understanding HNSCC.

Wnt/b-catenin signaling in HNSCC is involved in a variety of processes, such as proliferation, cancer cell stemness, and differentiation with mesenchymal traits (7, 8). With the epithelial-to-mesenchymal transition (EMT), cells lose epithelial characteristics and acquire mesenchymal features to gain mobility. EMT is crucial for tumor metastasis (9). EMT is driven by EMT-activating transcription factors (EMT-TF, including the SNAIL, TWIST, and ZEB families; ref. 10). The activation of EMT-TFs in cancer cells is associated with the maintenance of stemness properties (11), which links EMT to the concept of cancer stem cells (CSC). During EMT, cancer cells may resemble CSCs and exhibit enhanced self-renewal, metastasis, and drug resistance capabilities (11), characteristics evident in HNSCC (12). EMT may allow cancer cells to escape immune surveillance by various mechanisms (13). Similarly, CSCs have a negative impact on the effectiveness of immunotherapy (14). PD-L1, an immune inhibitory receptor with functions in cancer immune evasion, regulates EMT, the CSC-like phenotype, metastasis, and chemotherapeutic resistance (15). These findings suggest potential links among CSCs, EMT characteristics, and tumor immunity, although what those linkages are in the context of HNSCC remains unknown.

CMTM6 belongs to the CMTM-like MARVEL transmembrane domain–containing family (CMTM1–8) and is expressed at the plasma membrane of various cells (16). CMTM6 stabilizes PD-L1 protein expression to impair T-cell function (17, 18). CMTM6 increases PD-L1 expression without compromising antigen presentation by reducing MHC class I expression. Thus, the depletion of CMTM6 in cancer cells could enhance tumor-specific T-cell activity. CMTM6 synergizes with other immune checkpoint molecules, such as TIM-3 and B7-H3 (19). Elevated CMTM6 in gastric cancer is associated with a poor prognosis (19), and CMTM6 expression in combination with PD-L1 expression is a prognostic indicator in triple-negative breast cancer and pancreatic ductal adenocarcinoma (20). These findings suggest that CMTM6 may be a useful therapeutic target.

In this study, we found that, in HNSCC, CMTM6 is overexpressed and may be a prognostic IHC biomarker. Genetic ablation of CMTM6 reduces PD-L1 expression and restrains HNSCC cell proliferation. CMTM6 expression is correlated with Wnt/b-catenin signaling. In vitro depletion of CMTM6 affects the maintenance of stemness properties and inhibits TGFb-induced EMT in HNSCC cells. We also observed a positive association between expression of CMTM6 and immune checkpoints. In an allograft mouse model, the
Chen et al.
immunosuppressed tumor state was relieved and tumor growth was inhibited in the CMTM6 knockout group compared with the control group. We conclude that CMTM6 participates in the regulation of CSCs and EMT phenotypes in HNSCC cells and that targeting CMTM6 may be an alternative strategy for HNSCC treatment.

Materials and Methods

Antibodies

Primary antibodies for IHC, immunofluorescence, and immunoblotting: anti-CMTM6 (HPA026980) was obtained from Sigma-Aldrich. Anti-PD-L1 (#13684, #29122 and #64988), anti-β-Catenin (#8480), anti-CD44 (#3570), anti-ß-Mi1 (#6964), anti-Vimentin (#5741), anti-E-Cadherin (#3195), anti-N-Cadherin (#13116), anti-VISTA (#54979), anti-B7-H3 (#14058), anti-B7-H4 (#14572), anti-TIM-3 (#45208), anti-CD68 (#98941), anti-Histone H3 (#4499), and anti-lgG (#3900S) were all from Cell Signaling Technology. Anti-LAG-3 (ab209236) was from Abcam, anti-CD4 (GB11064) was from Servicebio, and anti-CMTM6 (GTX108450) was obtained from GeneTex.

Flow cytometry

FITC anti-human PD-L1 (393605), APC anti-mouse PD-L1 (124312), PerCP/Cyanine5.5 anti-mouse CD8α (100733), PE anti-mouse B7-H3 (124507), PE anti-mouse VISTA (150203), APC anti-mouse B7-H4 (139407), and APC anti-mouse TIM-3 (134007) were purchased from BioLegend and eFluor 450 anti-mouse CD4 (48-0041-80), PE anti-mouse PD-1 (12-9985-81), PE anti-mouse LAG-3 (12-2231-81), eFluor 506 Fixable Viability Dye (65-0866-14) were from eBioscience. APC-Cyanine7 anti-mouse CD45 (561037) and FITC anti-mouse CD3 (561798) were obtained from BD Pharmingen.

Human HNSCC tissues

All human studies were approved by the Medical Ethics Committee of the Hospital of Stomatatology, Wuhan University (Wuhan, China; 2016LUNSHENZI62). In this study, we used three sets of HNSCC tissue microarrays, derived from 210 cases of primary HNSCC, 69 cases of oral epithelial dysplasia, and 42 cases of normal oral mucosae. All tissue specimens were collected from the School and Hospital of Stomatatology, Wuhan University (Wuhan, China) from 2011 to 2016, and all patients who provided a specimen signed informed consent. The human HNSCC cell lines SCC4, SCC9, SCC15, and SCC25 (all from ATCC, 2014–2019) were maintained in F12/DMEM with 400 ng/ml hydrocortisone. CAL27 (obtained from ATCC, 2014) was cultured in DMEM/high glucose. The mouse HNSCC cell line SCC7 (obtained from Otwo Biotech, 2019) was cultured in RPMI1640 medium. Ten percent FBS (Gibco) and 1% penicillin/streptomycin were added to the above medium. The primary oral keratinocyte cell line (OKC) was cultured in serum-free keratinocyte medium (Gibco). Short tandem repeat authentication was performed for CAL27 and SCC4 in the experiment, but other cells have not been authenticated in the past year. All cell lines were used exclusively between passages 3 and 8 and were tested annually for Mycoplasma contamination by PCR (TransDetect). For the TGFβ-induced EMT assay, cells were treated with 8 ng/ml recombinant human TGFβ1 (PeproTech) for 1, 3, and 5 days. For the in vitro induction of PD-L1, SCC7 cells were treated with recombinant murine IFNγ (10 ng/mL, PeproTech) for 24 hours.

Cell proliferation and colony formation assays

For the cell proliferation assay, human HNSCC cell lines SCC4 or CAL27 were inoculated into 96-well flat-bottom plates (Corning) at 2,000 cells per well in the corresponding medium supplemented with 10% FBS. At 24, 48, and 72 hours, 20 μL CCK8 reagent (Dojindo) was added to each well, and the plates were incubated at 37°C for 2 hours. The absorbance was then measured at 450 nm using a BioTek plate reader (BioTek).

For the colony formation assay, 500 SCC4 or CAL27 cells were added to each well in a 6-well flat-bottomed plate in the corresponding medium supplemented with 10% FBS. After 10 days of culture, the cells were fixed using 4% paraformaldehyde and stained using crystal violet. The number of colonies was counted by ImageJ.

Sphere assay

Human HNSCC cell lines CAL27 (5,000 per plate) were cultured on 6-well Ultra-Low Attachment Microplates (Costar, Corning) in sphere medium (DMEM/F12 + N2 supplement (1%, R&D Systems) + B27 (1%, Gibco) + bFGF (20 ng/mL, Invitrogen) + EGF (20 ng/mL, Gibco)). Ten days later, spheres larger than 100 μm in diameter were counted. Sphere formation ratios were calculated as sphere number divided by 5,000.

Flow cytometry

Monolayer HNSCC and primary OKC cells were washed with PBS after trypsin digestion, and single-cell suspensions were stained with a cell surface PD-L1 antibody for 1 hour in PBS (2% FBS) at 4°C after Fc blocking. Samples were run on a flow cytometer (CytoFLEX S, Beckman Coulter), and data were analyzed by FlowJo 10 (V10.0.6, Tree Star). For mouse tumor-infiltrating lymphocyte (TIL) staining, tumor samples were digested in RPMI1640 medium with collagenase D (1 mg/mL, Roche), hyaluronidase (0.1 mg/mL, Biosharp), and DNase I (0.2 mg/mL, BioFroxx) at 37°C for 30 minutes after dissociation (gentleMACS Dissociator, Miltenyi Biotec). Then, the cells were filtered through a 70-μm strainer. The lymphocytes were separated with Lymphoprep (StemCell Technologies) according to the manufacturer’s protocol. The cell staining and detection methods were the same as described above.

The ALDEFLUOR Kit (StemCell Technologies) was used to analyze aldehyde dehydrogenase (ALDH) enzyme activity. A total of 10^6 cells/mL (CAL27 or SCC4) in ALDEFLUOR Assay Buffer were incubated with ALDEFLUOR reagent for 40 minutes at 37°C, and diethylaminobenzaldehyde was added to each sample as a negative control. The samples were analyzed on a CytoFLEX S, and data were analyzed in CytExpert.

Western blotting

Whole-cell extracts of cultured cells or sphere were lysed using M-PER Protein Extraction Reagent (containing protease and phosphatase inhibitors, Thermo Fisher Scientific). Nuclear proteins were extracted using a nucleoprotein extraction kit (Beyotime). For immunoblotting, the proteins were denatured by boiling, separated by 8%–10% SDS-PAGE, and transferred onto polyvinylidene difluoride membranes (Roche). After blocking with nonfat milk (5%) for 1 hour at room temperature, the blots were incubated overnight with the indicated antibodies at 4°C and were incubated with horseradish peroxidase–conjugated secondary antibodies (Biosharp) for 1 hour at room temperature on the subsequent day. Finally, the blots were...
detected with an ECL kit (Advanta), and images were visualized and quantified using the Odyssey System (LI-COR Biosciences).

Generation of knockout cell lines
The short hairpin RNA (shRNA) targeting sequences specific for the human and mouse CMTM6 were as follows: shCMTM6-1 (human): 5'-AGGTCAAGAAAGCATTGTTT-3'; shCMTM6-2 (human): 5’-CCTCAAGCAAGTGAAGTTA-3'; shCMTM6 (mouse): 5’-GGCC- TAACACAGAAGCTTTG-3'; shCtrl: 5’-GGATGATCGACGATTACA-3’ (18). A PLKO.1 vector encoding shRNA for a negative control (Sigma-Aldrich) or a CMTM6 target molecule was transfected into HEK293T cells together with psPAX2 and pMD2.G with Lipofectamine 2000 (Sigma-Aldrich). The culture lentiviral supernatant was harvested 48 hours after transfection. HNSCC cells were infected with the supernatants in the presence of 8 μg/mL polybrene (Sigma-Aldrich). Twenty-four hours after transduction, the cells were selected by 4 μg/mL puromycin (Sigma-Aldrich).

IHC and quantification
The 4-μm paraffin-embedded tissue sections were deparaffinized, rehydrated in xylene and an alcohol gradient, and heated in a sodium citrate solution for antigen retrieval. After endogenous peroxidase activity (3% hydrogen peroxide, 20 minutes) and nonspecific binding (goat or donkey serum, 30 minutes) were blocked, the sections were incubated overnight with the indicated antibodies at 4°C in a humidified box, and then incubated with the secondary biotinylated IgG antibody and an avidin–biotin–peroxidase reagent on the subsequent day. Finally, DAB reagent (Mab Biotechnologies) was used to detect these labeled antibodies, and the nucleus was stained with hematoxylin. Primary antibodies were replaced with IgG as a negative control (Supplementary Fig. S1A). All slides were scanned by an Aperio ScanScope CS scanner (Aperio) with background subtraction. Aperio ImageScope software (V11.1.2) was used for membrane, nuclear, or pixel quantification. The cancer or mucosal region of interest was selected for quantitative analysis. The histoscore of membrane and nuclear staining was calculated as a percentage of positive cells using the formula (total intensity of strong positive) – (total intensity of weak positive) + (total intensity of strong positive) × 2 + (total intensity of weak positive) × 1. The histoscore of pixel quantification was calculated as the total intensity/total cell number. The threshold for scanning positive cells was set according to the standard controls provided by Aperio (21).

Immunofluorescence
HNSCC cells were cultured in 10-mm laser confocal dishes (NEST Biotechnology) with medium containing 10% FBS for 24 hours, fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.5% Triton X-100 in PBS for 10 minutes at room temperature, and blocked with 5% BSA for 1 hour at 37°C. The cells were incubated overnight with the indicated antibodies at 4°C and then with the corresponding fluorescence-conjugated secondary antibody (Abbkine) for 1 hour at room temperature. Antibody Fluorescence Mounting Medium with DAPI (ZSGB-BIO) was used to mount the slides, and images were taken with a confocal microscope (FV1200, Olympus Life Science). For tumor sphere immunofluorescence, microspheres were collected in centrifuge tubes and then stained as described above; images were obtained by confocal microscopy with z-axis scanning.

ELISA
Tumor homogenates (100 mg tissue/mL PBS) were centrifuged at 3,000 rpm, supernatants were collected, and protein concentrations were normalized by a BCA Protein Kit (Beyotime).

Results
CMTM6 overexpression in HNSCC is associated with a poor prognosis
To gain insight into the role of CMTM6 in HNSCC progression, we detected CMTM6 expression by IHC analysis in custom-made HNSCC tissue microarrays (Fig. 1A). CMTM6 expression was significantly elevated in tumor tissues (n = 210) compared with normal mucosal (n = 42, P < 0.001) and dysplasia tissues (n = 69, P < 0.01; Fig. 1A and B). Specifically, CMTM6 was predominantly localized at the membrane of tumor cells, with some localization in the cytoplasm, and its expression was very similar to that of PD-L1 (http://www.proteinatlas.org/ENS0000812017–CD274/pathology). We next examined the relationships of CMTM6 expression with clinicopathologic parameters and patient survival. The results indicated that patients with HNSCC with a high pathologic grade (II and III) displayed higher CMTM6 expression than those with a low pathologic grade (I; Fig. 1A and C). Consistently, analysis of the HNSCC cohort in The Cancer Genome Atlas (TCGA) by UALCAN (22) showed that CMTM6 RNA expression was increased in patients with a higher pathologic grade (Fig. 1D). Furthermore, CMTM6 expression had a positive correlation with positive lymph node status, and tumor tissues from patients with lymph node metastasis stained more strongly [N(–) vs. N(+) P < 0.01; Fig. 1E] and F]. Next, we examined the prognostic value of CMTM6 expression in HNSCC. Kaplan–Meier analysis with the log-rank test showed that patients with higher CMTM6 expression had poorer outcomes, and vice versa [best cutoff (23) = 95.05, P = 0.0019, Fig. 1G; median cutoff = 179.91, P = 0.1283, Supplementary Fig. S1C]. However, CMTM6 expression was independent of tumor size (T1–T4), TPF chemother-apy, HPV status, and smoking or alcohol consumption. In addition, CMTM6 expression levels were not significantly altered in metastatic lymph nodes and HNSCC tissues from patients who underwent preoperative radiotherapy treatment or presented with recurrence...
compared with control HNSCC tissues (Supplementary Table S1). Altogether, these data indicate that CMTM6 overexpression is associated with aggressive cancer and a poor prognosis for patients with HNSCC.

**High CMTM6 expression is required for HNSCC proliferation**

To further explore the role of CMTM6 in HNSCC, we investigated CMTM6 expression in a normal OKC line and a series of HNSCC cell lines (SCC4, SCC9, SCC15, SCC25, and CAL27) by Western blot analysis (Fig. 2A). The surface PD-L1 expression of these cell lines was analyzed by flow cytometry. CMTM6 and PD-L1 protein expression was higher in most cancer cells than in normal epithelial cells (Fig. 2A and B). Next, we used two shRNAs to construct CAL27 and SCC4 cells with stable, low CMTM6 expression; CMTM6 knockdown cells showed an approximately 80% reduction in CMTM6 protein expression compared with cells treated with a scrambled shRNA. CMTM6

Figure 1.
CMTM6 is overexpressed and predicts a poor prognosis for patients with HNSCC. A, Representative IHC staining images of CMTM6 in normal mucosa and HNSCC tissues with different clinical pathologic grades (scale bar, 50 μm). B, Expression of CMTM6 protein in human HNSCC (n = 210) was higher than in oral mucosa (n = 42) and dysplasia (n = 69) by IHC analysis (**, P < 0.01; ***, P < 0.001). C, Quantification analysis of CMTM6 staining in HNSCC with different grades (I, n = 53; II, n = 121; III, n = 36; ***, P < 0.001 for I vs. III, I vs. IV, and II vs. IV; **, P < 0.01 for II vs. III and II vs. IV). Representative IHC staining of CMTM6 in metastasis-free (top, n = 138) and metastatic HNSCC tissue (bottom, n = 72; scale bar, 50 μm) and quantification analysis (F), N(−) = N0, N(+) = N1 + N2; **, P < 0.01. G, Kaplan-Meier survival analysis showed that patients with HNSCC with higher CMTM6 expression had a shortened overall survival (cutoff = 95.05). Error bar, SD.
depletion decreased PD-L1 expression, as shown by immunoblotting and flow cytometry analyses (Fig. 2C and D). Tumor-intrinsic PD-L1 is involved in regulating tumor growth in cervical cancer, ovarian cancer, and melanoma (24, 25). Our studies revealed that CMTM6 knockout led to repression of the self-renewal and colony-forming capacities of SCC4 and CAL27 cells (Fig. 2E and F; Supplementary Fig. S2), perhaps explaining the finding that CMTM6 expression was associated with a high pathologic grade. Together, these findings suggest that CMTM6 may promote the proliferation of HNSCC cell lines.

CMTM6 depletion reduced nuclear translocation of β-catenin in HNSCC

The abovementioned results prompted us to further explore the mechanism of CMTM6 in HNSCC progression. Next, we analyzed most of the CMTM6-associated genes in the TCGA HNSCC cohort using the LinkedOmics database (26). As shown in the volcano plot, CTNNB1 (gene encoding β-catenin) exhibited the highest positive correlation with CMTM6 (Fig. 3A), and we observed a statistically significant correlation between CMTM6 and CTNNB1 by Spearman correlation analysis (n = 520, P = 1.933E-47, R = 0.5768; Fig. 3B). Numerous studies have shown that the Wnt/β-catenin signaling pathway plays roles in HNSCC tumorigenesis, and this pathway is involved in regulating tumor biological features, such as the maintenance of CSC phenotypes, proliferation, and EMT (7). Subsequently, we examined the relationship between CMTM6 and β-catenin with our HNSCC tissue microarray. The IHC staining results demonstrated that tumor regions with high CMTM6 expression contained abundant β-catenin (Fig. 3C). In contrast, β-catenin expression was reduced in tumor areas lacking CMTM6 (Fig. 3C). The positive correlation between CMTM6 and β-catenin expression was confirmed by analysis of protein (n = 210, P < 0.0001, R = 0.5292; Fig. 3D). To validate these findings, we performed immunofluorescence staining of CMTM6-knockout cells and control cells. CMTM6 depletion with shRNA
lentivirus decreased β-catenin nuclear translocation (Fig. 3E). The Western blotting results showed that although total β-catenin was not significantly affected, nuclear β-catenin amounts were reduced in CMTM6-deficient cells compared with control cells (Fig. 3F). The above data indicate that CMTM6 may participate in the regulation of multiple biological characteristics of HNSCC by affecting the canonical Wnt/β-catenin signaling pathway.

Elevated CMTM6 sustains CSC phenotypes in HNSCC

Because the Wnt/β-catenin signaling pathway is involved in the functions of HNSCC CSCs (8), we determined whether CMTM6 plays a role in the acquisition of stem cell–like properties. Studies have shown that tumor spheres exhibit more CSC features than their adherent counterparts in HNSCC (27). The coimmunofluorescent staining of CMTM6 and several CSC markers (ALDH1, CD44 and BMI1; ref. 12) in HNSCC spheres indicated that CMTM6 was highly expressed in cells with strong stemness properties. This elevated expression of CMTM6 in spheres was validated by Western blotting (Fig. 4B). Enrichment of PD-L1 in CD44⁺ CSCs may contribute to immune evasion by HNSCC (28). To investigate whether CMTM6 can directly affect the maintenance of CSCs, we measured ALDH activity in CMTM6-knockout cells and found that the percentages of ALDHhigh cells among CMTM6-depleted CAL27 and SCC4 cells were decreased (Fig. 4C). We then performed tumor sphere formation assays to evaluate the self-renewal ability of these two groups of cells. CMTM6-silenced cells formed fewer spheres (Fig. 4D). This finding was verified by immunofluorescence and Western blot analyses: the expression of several CSC-related markers was downregulated after CMTM6 depletion (Fig. 4E and F), indicating the role of CMTM6 in HNSCC cell self-renewal. To validate our results, we analyzed

Figure 3.

CMTM6 expression has a positive correlation with the Wnt/β-catenin pathway in HNSCC. A, Volcano plot of CMTM6-associated genes by Spearman correlation coefficient test in the LinkedOmics database. The gray dashed line of \( P = 0.05 \) was plotted. B, Expression correlation between CMTM6 and CTNNB1 RNA expression in the TCGA HNSCC database. Correlation was analyzed using Spearman correlation coefficient test, \( n = 520 \). C, Representative IHC staining of CMTM6 and β-catenin in HNSCC specimens (scale bar, 50 μm). D, Pearson correlation analysis of CMTM6 and β-catenin protein expression in HNSCC tissue microarray (\( n = 210 \)). E, The distribution of β-catenin (green) in CMTM6 knockdown and control CAL27 cells was analyzed by immunofluorescence (scale bar, 20 μm), and the red arrow indicates the location of the nucleus. F, Western blot analysis showed β-catenin expression levels in total or nuclear proteins of the control and CMTM6-silenced groups. The data shown are representative of three experiments (E and F).
Figure 4. CMTM6 is expressed in cancer stem cells and promotes stemness properties. A, Representative coimmunofluorescent staining images of CMTM6 (green) and CSC markers: ALDH1 (red), BMI1 (red), and CD44 (green) in tumorspheres (scale bar, 50 μm). B, The expression of CMTM6 and CSC-related proteins in spheres and adherent cells was detected by Western blotting. C, An ALDEFLUOR assay was conducted in CMTM6-deficient and control cells, and the percentage of ALDHhigh cells was quantified by flow cytometry (**, P < 0.01; ****, P < 0.001); error bar, SD. D, Representative images and quantitative analysis of a sphere formation assay (**, P < 0.01); error bar, SD. E, Immunofluorescence images show the expression of CSC markers BMI1 (green) and CD44 (red) after CMTM6 knockout (scale bar, 20 μm). F, Western blot results confirmed that CMTM6 knockout reduced the expression of CSC-related proteins. G, CMTM6 was positively correlated with CSC genes in the TCGA HNSCC database using Spearman correlation coefficient test, n = 520. The data shown are representative of three experiments (A–F).
the association of CMTM6 RNA expression with the expression of CSC-related genes (CD44, ALDH1A1, ALDH1B1, and BM11) in the TCGA HNSCC cohort. Expression of CMTM6 and these CSC-related genes was positively correlated (Fig. 4G). Collectively, these data demonstrate that CMTM6 plays a role in acquisition of stem cell-like properties in HNSCC.

**CMTM6 is involved in regulating EMT in HNSCC**

Evidence suggests an association between EMT and the acquisition of CSC-like properties in various types of cancer (11), including HNSCC (12). TGFβ is an inducer of EMT that can also mediate PD-L1 induction (29), indicating that PD-L1 might play a role in modulating EMT. To investigate the connection between CMTM6 and EMT, we first analyzed the correlation between CMTM6 and EMT-related genes in the TCGA HNSCC datasets. Indeed, CMTM6 RNA amounts were significantly positively associated with the amounts of most mesenchymal markers (VIM, FN1, and CDH2) and EMT-TFs (SNAIL, TWIST, and ZEB family; Fig. 5A; Supplementary Fig. S3), with a particularly strong association with the ZEB family (Fig. 5A). In addition, cancer cell expression of PD-L1 is regulated by the miR-200/ZEB1 axis in non–small cell lung cancer (NSCLC) cells (30). These findings prompted us to determine whether CMTM6 is involved in regulating EMT in HNSCC; thus, we performed a TGFβ-induced EMT assay in HNSCC cells as described previously (31) and detected potential changes in CMTM6 expression. The immunoblotting results showed that CMTM6 expression gradually increased during EMT progression (Fig. 5B). When CMTM6 was knocked out in squamous cancer cells, the induction of EMT by TGFβ was inhibited. This finding was confirmed by both immunofluorescence and Western blot assays (Fig. 5C and D). Together, our observations suggest that CMTM6 may affect the induction of EMT in HNSCC.

**Expression of CMTM6 correlated with immune checkpoint in human HNSCC**

The PD-1/PD-L1 interaction leads to T-cell dysfunction and exhaustion, which helps tumor cells evade immune surveillance (32), and CMTM6 has been identified as a regulator of PD-L1 expression. Therefore, to determine whether CMTM6 also plays a role in T-cell tumor immunity in HNSCC, we analyzed its correlation with RNA expression of several immune checkpoint molecules in the TCGA HNSCC datasets. CMTM6 expression was positively associated with expression of these genes, especially with HAVCR2 (TIM-3; Fig. 6A; Supplementary Table S2). Our previous studies investigated the expression and function of certain immune checkpoints in HNSCC. To ascertain whether CMTM6 protein amounts are also associated with T-cell dysfunction, we conducted Pearson correlation analysis with CMTM6, PD-L1, LAG-3, TIM-3, VISTA, B7-H4, and B7-H3 expression in HNSCC tissues based on quantitative IHC results. Consistently, CMTM6 protein amounts were positively correlated with the amounts of these immune checkpoint markers (Fig. 6B).
Taken together, these results suggest that CMTM6 may play a role in T-cell suppression in HNSCC.

CMTM6 silencing inhibits tumor growth and enhances immune response in murine HNSCC

Studies have shown that targeting the upstream regulator of PD-L1 is an alternative strategy in melanoma (33). As a positive regulator of PD-L1 protein expression, can CMTM6 also amplify tumor-specific immunity? To address this question, we conducted an in vivo experiment with an immunocompetent HNSCC allograft mouse model (34, 35). Although PD-L1 expression is low in SCC7 cells, it was increased after stimulation with IFNγ, which was also increased in subcutaneously inoculated tumor tissue (Fig. 7A and B). Moreover, we verified that CMTM6 knockdown inhibited IFNγ-induced PD-L1 expression in SCC7 cells (Fig. 7B; Supplementary Fig. S4). Subsequently, wild-type, CMTM6-knockout, or scrambled shRNA SCC7 cells were injected subcutaneously into C3H/He mice. We then isolated SCC7 cells from the transplanted tumors at day 21 and performed flow cytometry to detect cell surface PD-L1 expression, which was lower in the CMTM6-depleted group (Fig. 7C). As

Figure 6.
Increased CMTM6 is correlated with immune checkpoint members in HNSCC. A, Expression correlation between CMTM6 and immune checkpoint gene RNA amounts in the TCGA HNSCC database, n = 520, CMTM6 (CMTM6), PD-L1 (CD274), PD-1 (PDCD1), VISTA (VSIR), B7-H3 (CD276), B7-H4 (VTCN1), LAG-3 (LAG3), CTLA-4 (CTLA4), and TIM-3 (HAVCR2). B, Pearson correlation analysis of CMTM6 and several immune checkpoint expressions in human HNSCC tissue microarray based on the IHC results, n = 116.
anticipated, the tumor growth of CMTM6-knockdown SCC7 cells was reduced compared with that of control cells (Fig. 7D). HNSCC tumors are immunosuppressive and characterized by impaired T-cell function and the accumulation of immunosuppressive cells (15). Therefore, we examined the effect of CMTM6 depletion on cancer immunity. The populations of CD4+ and CD8+ T cells in TILs were significantly elevated after CMTM6 silencing, as shown by flow cytometry and IHC assays (Fig. 7E; Supplementary Figs. S5 and S6A). To confirm that CMTM6 knockdown inhibits tumor growth in a manner dependent on T-cell activity, we used anti-CD8+ to deplete CD8+ cells. CD8+ depletion significantly reduced the difference in tumor size between the two groups (Fig. 7F). Compared with the control group, the shCMTM6 group showed a significant decrease in the expression of the other five immune checkpoints in T cells, except for B7-H4 (Fig. 7G–I; Supplementary Fig. S6B and S6C). In addition, ELISA results showed that IFNγ, TNFα, and Granzyme B levels in tumor tissue were increased significantly in the CMTM6-depleted group (Supplementary Fig. S6D), suggesting T lymphocyte activation after CMTM6 knockout in vivo. Thus, these data reveal that CMTM6 depletion may improve antitumor immunity by increasing numbers of effector T cells in HNSCC.

Discussion

HNSCC is a heterogeneous tumor with high metastasis and recurrence rates, and there has been little improvement in 5-year survival over the past decades (6). EMT is part of the process of tumor metastasis (37), especially in squamous cell carcinoma (38). Briefly, cancer cells undergoing EMT lose their epithelial characteristics and gain mobility, which facilitates invasion and dissemination (9). Moreover, such cells are closely related to another small population of cells, CSCs, that may be tumor-initiating cells, the main culprits of tumor recurrence and chemotherapy resistance (11). In addition, CSC and EMT phenotypes may mediate tumor immunosuppression (13, 14); CD44+ HNSCC cells can achieve immune escape by high PD-L1 expression (28), and a subset of TGFβ-responsive CSCs were reported to suppress T-cell antitumor immunity and drive tumor relapse by regulating CD80 expression in a squamous cell carcinoma mouse model (39). EMT induced by the EMT-Tf Snail can promote tumor metastasis by accelerating immunosuppression (40). Upon Snail knockout in ovarian cancer cells, the number of CD8+ T cells was increased; in contrast, the population of MDSCs among TILs was decreased (41). These findings revealed a relationship among EMT, CSCs, and tumor immunity that facilitates tumor progression. These findings prompted us to rethink the current therapeutic strategies for developing more effective treatments.

Immunotherapies based on immune checkpoints have emerged as a treatment option for various cancer types. Blockade of the PD-L1/PD-1 interaction with mAbs represents a milestone for anticancer immunotherapy. However, it is effective only in a small subset of patients (42). Therefore, it is necessary to explore alternative therapies or combined strategies to increase the drug response rate. Tumors expressing PD-L1 not only mediate immunosuppression but also have tumor-intrinsic functions in regulating EMT, CSC phenotypes, and drug resistance (15). For instance, PD-L1 promotes cell proliferation in cervical cancer (25), ovarian cancer, and melanoma (24); PD-L1 knockdown inhibits stem cell–like properties in breast cancer through the PI3K/AKT pathway (43). Moreover, EMT can induce PD-L1 accumulation on cancer cells through the miR-200/ZEB1 axis in NSCLC (30). In addition, PD-L1 is preferentially expressed on CSCs and facilitates CSC immune evasion in a STT3-dependent manner (29). Coincidentally, correlation analysis results showed that STT3 has a positive correlation with CMTM6 RNA expression. High PD-L1 expression on CD44+ cells promotes a stronger immunosuppressive effect in HNSCC (28). This evidence suggests that we seek new therapeutic strategies besides antibody blockade. Currently, directly targeting the modulation of PD-L1 expression has yielded promising results in multiple myeloma (44). Ablation of Nrf2, a gene upstream of PD-L1, enhanced tumor immunity in a melanoma mouse model (33). Because CMTM6 has been identified as a vital regulator of PD-L1, we speculated that CMTM6 may affect the above biological functions by modulating PD-L1 expression.

To verify this hypothesis, we first analyzed CMTM6 expression in HNSCC by IHC. CMTM6 was highly expressed in HNSCC, and its expression pattern was similar to that of PD-L1. In addition, patients with high CMTM6 expression had a poor prognosis, which was consistent with previous reports that PD-L1 is a poor prognostic predictor of HNSCC (45). Furthermore, CMTM6 was found to be enriched in high-grade HNSCC tumor samples, which suggested that CMTM6 overexpression is associated with tumor progression. Subsequently, we constructed stable CMTM6-knockdown HNSCC cell lines and observed a decrease in PD-L1; moreover, cell proliferation was suppressed after CMTM6 depletion. This result is not contradictory to the finding that PD-L1 regulates tumor proliferation (15, 24, 25). Gene-wide correlation analysis based on the TCGA HNSCC database identified that CTNNB1 was the gene most closely related to CMTM6. β-Catenin is part of the Wnt signaling pathway (46). Moreover, there is evidence that the Wnt/β-catenin pathway plays a role in regulating CSC/EMT phenotypes in HNSCC (7, 8), and activation of this pathway may prevent antitumor immunity in melanoma (47). The role of the Wnt pathway in tumor immunity is being discovered (48). Wnt signaling participates in the modulation of PD-L1 in triple-negative breast cancer, perhaps to help cancer cells escape immune surveillance (49). Our results indicate that CMTM6 can indeed affect the Wnt pathway. Thus, we investigated whether CMTM6 affects EMT and CSC phenotypes. As expected, CMTM6 knockdown inhibited stem cell–like properties and TGFβ-induced EMT to varying degrees. This finding suggested that CMTM6 possesses tumor-intrinsic functions analogous to those of PD-L1. CMTM6 has been reported to have synergetic correlations with multiple immune checkpoint inhibitors (19), and CMTM6 depletion enhanced the cytotoxic functions of T cells (17, 18). To investigate the relationship between CMTM6 and...
immune checkpoints in HNSCC, we conducted Pearson correlation analysis with CMTM6 and other recognized immune checkpoints in the TCGA database and our HNSCC tissue microarrays. We observed positive correlations between CMTM6 and RNA and protein expression of the majority of immune checkpoint markers. Subsequently, we explored the potential of CMTM6 as an immunotherapy target using an immunocompetent HNSCC mouse model. Our results showed that knocking out CMTM6 not only inhibited tumor growth but also relieved the immunosuppressive state by increasing T-cell number and function; moreover, the expression of the immune checkpoint molecules PD-1, TIM-3, VISTA, LAG-3, and B7-H3 in TIL-T cells was decreased in the CMTM6 knockdown group, which was consistent with our previous TCGA and IHC correlation data. In addition, we noted that although not all HNSCC cell lines constitutively overexpress PD-L1, expression of this protein could be induced in the presence of IFNγ, indicating dynamic PD-L1 regulation in tumorigenesis. Treatment efficacy of PD-L1 antibody alone in SCC7 tumors was not satisfactory (50), and the reasons for this difference may be that CMTM6-regulated PD-L1 expression was not affected by IFNγ in the tumor microenvironment and that CMTM6 gene knockout affected the intrinsic functions of tumor cells. In C897 T-cell–depleted mice, the tumors in the shCMTM6 group were not significantly smaller than those in the control group, perhaps due to the slight PD-L1 expression in the SCC7 cell line and the weak CSC/EMT-related abilities.

In summary, we demonstrate that CMTM6 is overexpressed in HNSCC and is associated with positive lymph node status and high pathologic grade. Moreover, high CMTM6 expression indicates a poor prognosis. In addition, CMTM6 is highly correlated with the Wnt/β-catenin signaling pathway through which CMTM6 may affect the maintenance of CSCs and EMT phenotypes. We also explored the relationship between CMTM6 and tumor immunity. The correlation analysis results suggest a synergistic relationship between CMTM6 and immune checkpoint expression. In vivo experiments demonstrated that knocking out CMTM6 delays tumor growth, enhances T-cell function, and reduces the number of exhausted T cells. CMTM6 regulates PD-L1 independently of the IFN pathway. Therefore, compared with antibody blockade, targeting CMTM6 could actively inhibit the homeostatic feedback loop of IFN-induced PD-L1 expression in the tumor microenvironment. CMTM6 may be a useful immunotherapy, especially for patients with resistance to anti-PD-1/PD-L1 treatments. In addition, our study linked CSC/EMT phenotypes to tumor immunity. However, many problems remain to be solved, such as the lack of suitable drugs and an incomplete understanding of CMTM6 regulation in tumors. Nevertheless, CMTM6 may be a therapeutic target for the treatment of cancer.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**

Conception and design: L. Chen, Z.-J. Sun
Development of methodology: L. Chen, Z.-J. Sun
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Chen, Q.-C. Yang, L.-L. Yang, J.-F. Liu, H. Li, Z.-J. Sun
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Chen, Q.-C. Yang, L.-L. Yang, X. Xiao, L.-L. Bu, Z.-J. Sun
Writing, review, and/or revision of the manuscript: L. Chen, W.-F. Zhang, Z.-J. Sun

**Study supervision:** W.-F. Zhang, Z.-J. Sun

**Acknowledgments**

This work was supported by National Natural Science Foundation of China (81874131, 81672668, and 81672667). The authors thank Shu-Yan Liang and Yin Liu from Wuhan Institute of Biotechnology for their excellent technical assistance on flow cytometry.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 27, 2019, revised October 14, 2019; accepted November 22, 2019, published first November 26, 2019.


Cancer Immunology Research

Targeting CMTM6 Suppresses Stem Cell–Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

Lei Chen, Qi-Chao Yang, Yi-Cun Li, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/2326-6066.CIR-19-0394

Supplementary Material
Access the most recent supplemental material at:
http://cancerimmunolres.aacrjournals.org/content/suppl/2019/11/26/2326-6066.CIR-19-0394.DC1

Cited articles
This article cites 50 articles, 7 of which you can access for free at:
http://cancerimmunolres.aacrjournals.org/content/8/2/179.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://cancerimmunolres.aacrjournals.org/content/8/2/179.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link:
http://cancerimmunolres.aacrjournals.org/content/8/2/179.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.